期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 58, 期 3, 页码 1320-1336出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm501662b
关键词
-
资金
- Spanish Ministerio de Economia y Competitividad
- FEDER [SAF2011-26611]
- Fundacion Seneca-CARM [08666/PI/08, 15354/PI/10, Exp. 19020/FPI/13]
- European Union [267143, COST CM1105]
A library of over 20 cycloplatinated compounds of the type [Pt(dmba-R)LCl] (dmba-R = C,N-dimethylbenzylamine-like ligand; R being MeO, Me, H, Br, F, CF3, and NO2 substituents in the R-5 or R-4 position of the phenyl ring; L = DMSO and P(C6H4CF3-p)(3)) has been prepared. All compounds are active in both human ovarian carcinoma A2780 cells and cisplatin-resistant A2780cisR cells, with most of the DMSO platinum complexes exhibiting IC50 values in the submicromolar range in the A2780 cell line. Interestingly, DMSO platinum complexes show low cytotoxicity in the nontumorigenic kidney cell line BGM and therefore high selectivity factors SF. In addition, some of the DMSO platinum complexes effectively inhibit angiogenesis in the human umbilical vein endothelial cell line EA.hy926. These are the first platinum(II) complexes reported to inhibit angiogenesis at a close concentration to their IC50 in A2780 cells, turning them into dual cytotoxic and antiangiogenic compounds.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据